Therapies directed against vascular endothelial growth factor (VEGF) and its major receptor, VEGF‐receptor‐2 (VEGFR2), whilst effective in a number of cancers, are not without side‐effects due to the role this signalling pathway plays in vascular homeostasis 3. The gene discussed is VEGFA; the disease is cancer.